연구동향 분석
박사

Clinical Utility of fecal Neutrophil Gelatinase-Associated Lipocalin and Calprotectin in Clostridioides (Clostridium) difficile infection = Clostridioides (Clostridium) difficile 감염에서 대변 NGAL과 calprotectin의 임상적 유용성

이주원 2019년

논문상세정보
인용/피인용
' Clinical Utility of fecal Neutrophil Gelatinase-Associated Lipocalin and Calprotectin in Clostridioides (Clostridium) difficile infection = Clostridioides (Clostridium) difficile 감염에서 대변 NGAL과 calprotectin의 임상적 유용성' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • C.difficile
  • calprotectin
  • ngal
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
13 0

0.0%

' Clinical Utility of fecal Neutrophil Gelatinase-Associated Lipocalin and Calprotectin in Clostridioides (Clostridium) difficile infection = Clostridioides (Clostridium) difficile 감염에서 대변 NGAL과 calprotectin의 임상적 유용성' 의 참고문헌

  • Zhang A, Cai Y, Wang PF, Qu JN, Luo ZC, Chen XD, et al. Diagnosis and prognosis of neutrophil gelatinase-associated lipocalin for acute kidney injury with sepsis: a systematic review and meta-analysis. Critical Care 2016;20(41):1-13.
  • Wright EK. Calprotectin or Lactoferrin: Do They Help. Dig Dis 2016;34:98- 104.
  • Valiente E, Cairns M, Wren BW. The Clostridium difficile PCR ribotype 027 lineage: a pathogen on the move. Clin Microbiol Infect 2014;20:396-404.
  • Thorsvik S, Damas JK, Granlund AV, Flo TH, Bergh K, stvik AE, Sandvik AK. Fecal neutrophil gelatinase-associated lipocalin as a biomarker for inflammatory bowel disease. J Gastroenterol Hepatol 2017;32:128-135.
  • Sipponen T, Kolho KL. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand J Gastroenterol 2014;50(1):74-80.
  • Singer E, Marko L, Paragas N, Barasch J, Dragun D, M ller DN, Budde K, Schmidt-Ott KM. Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications. Acta Physiol (Oxf) 2013;207(4):663-672.
  • Senchyna F, Gaur R, Gombar S, Truong CY, Schroeder LF, Banaei N, Clostridium difficile PCR Cycle Threshold Predicts Free Toxin. Journal of Clinical Microbiology 2017;55(9):2651-2660.
  • Ruscio MD, Vernia F, Ciccone A, Frieri G, Latella G. Surrogate Fecal Biomarkers in Inflammatory Bowel Disease: Rivals or Complementary Tools of Fecal Calprotectin? Inflamm Bowel Dis 2017;24(1):78-92.
  • Paalanne N, Husso A, Salo J, Pievilainen O, Tejesvi MV, Koivusarri P, et al. Intestinal microbiome as a risk factor for urinary tract infections in children. Eur J Clin Microbiol Infect Dis 2018;37:1881-1891.
  • Nakashige TG, Zhang B, Krebs C, Nolan EM. Human calprotectin is an ironsequestering host-defense protein. Nature Chemical Biology 2015;11(10):765- 771.
  • McDonald LC, Gerding D, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases 2018;66:e1-48.
  • Manceau H, Cattoir VC, Puy H, Peoc’h K. Fecal calprotectin in inflammatory bowel diseases: update and perspectives. Clin Chem Lab Med 2017;55(4):474- 483.
  • M rtensson J, Bellomo R. The Rise and Fall of NGAL in Acute Kidney Injury. Blood Purif 2014;37:304-310.
  • Lessa FC, Yi M, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of Clostridium difficile Infection in the United States. N Engl J Med 2015;372(9):825-834.
  • Leffler DA, Lamont J. Clostridium difficile Infection. N Engl J Med 2015; 372(16):1539-1548.
  • Lawson PA, Citron DM, Tyrrell KL, Finegold SM. Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O’Toole 1935) Prevot 1938. Anaerobe 2016;40:95-99.
  • Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342(6):390-397.
  • Kim YS, Han D, Kim YH, Kim WH, Kim JS, Kim HS, et al. Incidence and clinical features of Clostridium difficile infection in Korea: a nationwide study. Epidemiol. Infect 2013;141:189-194.
  • Ghose C. Clostridium difficile infection in the twenty-first century. Emerging Microbes & Infections 2013;2(1):1-8.
  • Foster AJ, Smyth M., Lakhani A, Jung B, Brant RF, Jacobson K. Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients. World J Gastroenterol 2019;25(10):1266-1277.
  • Farooq PD, Urrunaga N, Tang DM, Rosenvinge EC. Pseudomembranous Colitis. Dis Mon 2015;61(5):181-206.
  • Epitope Diagnostics, I. Quantitative Fecal Calprotectin ELISA Kit. Available from: http://www.epitopediagnostics.com/kt849. Accessed: 23 May 2019.
  • Debast SB, Bauer M, Kuijper EJ, on behalf of the Committee. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014;20:1-26.
  • Davies KA, Longshaw CM, Davis GL, Bouza E, Barbut F, Barna Z, et al. Underdiagnosis of Clostridium diffi cile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium diffi cile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis 2014;14:1208-1219.
  • D'Angelo F, Felley C, Frossard JL. Calprotectin in Daily Practice: Where Do We Stand in 2017? Digestion 2017;95:293-301.
  • Cho SY, Nam Y, Soh YS, Park TS, Lee HJ. Molecular epidemiology of toxigenic Clostridium difficile isolates in Korea. Epidemiol. Infect 2014;142: 1651-1652.
  • Cepheid. Xpert C. difficile. Available from: http://www.cepheid.com/us/cepheid-solutions/clinical-ivd-tests/healthcareassociated- infections/xpert-c-difficile. Accessed: 26 May 2019.
  • Budzynska A, Gawron-Kiska M, Nowakowska-Dulawa E, Spiewak J, Lesinska M, Kukla M, et al. Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) correlates with clinical and endoscopic activity in ulcerative colitis but fails to perdict activity in Crohn's disease. J Physiol Pharmacol 2017;68(6):859-865.
  • Bartlett JG. Clostridium difficile Infection. Infect Dis Clin N Am 2017;31:489- 495.
  • Balsells E, Shi T, Leese C, Lyell I, Burrows J, Wiuff C, Campbell H, Kyaw MH, Nair H. Global burden of Clostridium difficile infections: a systematic review and meta-analysis. Journal of Global Health 2019;9(1):1-20.